StockDrifts LogoStockDrifts

Baskan Bio Pharmaceutical 354390

Company
바스칸바이오제약Baskan Bio Pharmaceutical
Insiders
1
Buys
1
Total Value
₩77M ($53K)
Avg Return
-16.36%
Last Filing
2025-09-01

Baskan Bio Pharmaceutical (354390) has 1 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩77M ($53K) in reported transaction value. The earliest filing StockDrifts holds for Baskan Bio Pharmaceutical is dated 2025-09-01; the most recent is 2025-09-01. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -16.36%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2025-09-01BUYMarket Buy
민천기
Min Cheon-gi
Outside Director13.0K₩5,900-16.4%₩77M ($53K)

Frequently asked questions

Who has been buying Baskan Bio Pharmaceutical stock?
1 distinct insiders have filed 1 disclosed insider purchases in Baskan Bio Pharmaceutical (354390), most recently on 2025-09-01. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Baskan Bio Pharmaceutical have?
Baskan Bio Pharmaceutical has 1 buy-side and 0 sell-side disclosures on record, covering ₩77M ($53K) in total reported value, spanning 2025-09-01 to 2025-09-01.
Where does StockDrifts get Baskan Bio Pharmaceutical insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Baskan Bio Pharmaceutical. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.